JP2020526206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526206A5 JP2020526206A5 JP2020500887A JP2020500887A JP2020526206A5 JP 2020526206 A5 JP2020526206 A5 JP 2020526206A5 JP 2020500887 A JP2020500887 A JP 2020500887A JP 2020500887 A JP2020500887 A JP 2020500887A JP 2020526206 A5 JP2020526206 A5 JP 2020526206A5
- Authority
- JP
- Japan
- Prior art keywords
- cgamp
- sample
- test
- cells
- test compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762530661P | 2017-07-10 | 2017-07-10 | |
| US62/530,661 | 2017-07-10 | ||
| PCT/US2018/041480 WO2019014246A1 (en) | 2017-07-10 | 2018-07-10 | TARGETING CHROMOSOMIC INSTABILITY AND SIGNALING OF CYTOSOLIC DNA IN AVAL FOR THE TREATMENT OF CANCER |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526206A JP2020526206A (ja) | 2020-08-31 |
| JP2020526206A5 true JP2020526206A5 (enExample) | 2022-08-18 |
| JP7197556B2 JP7197556B2 (ja) | 2022-12-27 |
Family
ID=63036469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500887A Active JP7197556B2 (ja) | 2017-07-10 | 2018-07-10 | がん治療のための染色体不安定性および下流サイトゾルｄｎａシグナル伝達をターゲティングする方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11821042B2 (enExample) |
| EP (1) | EP3652349A1 (enExample) |
| JP (1) | JP7197556B2 (enExample) |
| KR (1) | KR20200037796A (enExample) |
| CN (1) | CN111295454A (enExample) |
| AU (1) | AU2018300007A1 (enExample) |
| BR (1) | BR112020000477A2 (enExample) |
| CA (1) | CA3069515A1 (enExample) |
| IL (1) | IL271849A (enExample) |
| MX (1) | MX2020000406A (enExample) |
| SG (1) | SG11202000132WA (enExample) |
| WO (1) | WO2019014246A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017318610B2 (en) * | 2016-09-02 | 2021-12-09 | The Board Of Trustees Of The University Of Illinois | KIF13B-derived peptide and method of inhibiting Angiogenesis |
| BR112020000477A2 (pt) | 2017-07-10 | 2020-07-21 | Cornell University | ataque à instabilidade cromossômica e sinalização de dna citosólico a jusante para tratamento de câncer |
| JP7226763B2 (ja) * | 2017-08-17 | 2023-02-21 | 国立大学法人山口大学 | 癌幹細胞における薬物耐性の低減剤、癌幹細胞における転移能の抑制剤及び癌の転移性再発リスクを予測する方法 |
| EP3987291A1 (en) * | 2019-06-21 | 2022-04-27 | IFM Due, Inc. | Methods of treating cancer |
| EP4110343B1 (en) * | 2020-02-19 | 2026-04-08 | Instituto De Biologia Molecular E Celular - IBMC | 4-pyrrolidin-1-yl-5-p-tolyl-thieno[2,3-d] pyrimidine for use in the treatment of aging-associated and premature aging diseases through restored chromosomal stability and inhibition of cellular senescence |
| EP4160181A4 (en) * | 2020-05-28 | 2024-08-07 | Wang, Daoxiang | METHOD FOR PREPARING MULTIPLE STAINING SECTIONS FOR A CYTOPATHOLOGY SAMPLE |
| US20230324392A1 (en) * | 2020-09-02 | 2023-10-12 | Memorial Sloan Kettering Cancer Center | Methods and compositions for targeting cytosolic dsdna signaling in chromosomally unstable cancers |
| EP4326726A4 (en) * | 2021-04-23 | 2025-03-26 | Baruch S. Blumberg Institute | METHODS, KITS AND COMPOSITIONS FOR REDUCING CHROMOSOMALIC INSTABILITY IN CANCER CELLS |
| CN113341154B (zh) * | 2021-05-14 | 2024-11-05 | 医工瑞思(福建)工程研究中心有限公司 | 一种检测血栓或凝血相关疾病的生物标志物及其应用 |
| WO2023028564A1 (en) | 2021-08-26 | 2023-03-02 | Volastra Therapeutics, Inc. | Spiro indoline inhibitors of kif18a |
| CN115354078B (zh) * | 2022-09-02 | 2023-07-07 | 中山大学附属第一医院 | 骨肉瘤检测标记物及其应用 |
| EP4488389A1 (en) * | 2023-07-05 | 2025-01-08 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Signature for the prognosis of brain metastasis relapse |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962091A (en) | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
| WO1994007529A1 (en) | 1992-09-25 | 1994-04-14 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| AU1508899A (en) | 1997-12-02 | 1999-06-16 | Chong Kun Dang Corporation | Pharmaceutical composition comprising cyclosporin solid-state microemulsion |
| GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| PT2934598T (pt) | 2012-12-19 | 2018-07-24 | Univ Texas | Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero |
| WO2015036643A2 (es) | 2013-09-13 | 2015-03-19 | Sierra Jiménez Angels | Marcador para predecir metástasis del cancer de mama |
| BR112016020897A2 (en) * | 2014-03-11 | 2018-01-23 | The Council Of The Queensland Institute Of Medical Research | Determination of cancer aggressiveness, prognosis, and responsiveness to treatment |
| WO2016044790A1 (en) * | 2014-09-19 | 2016-03-24 | Memorial Sloan-Kettering Cancer Center | Methods for treating brain metastasis |
| US10329258B2 (en) | 2015-04-30 | 2019-06-25 | University Of Washington | CGAS in systemic lupus erythematosus (SLE) |
| BR112020000477A2 (pt) | 2017-07-10 | 2020-07-21 | Cornell University | ataque à instabilidade cromossômica e sinalização de dna citosólico a jusante para tratamento de câncer |
-
2018
- 2018-07-10 BR BR112020000477-4A patent/BR112020000477A2/pt not_active Application Discontinuation
- 2018-07-10 KR KR1020207003861A patent/KR20200037796A/ko not_active Withdrawn
- 2018-07-10 MX MX2020000406A patent/MX2020000406A/es unknown
- 2018-07-10 EP EP18746496.1A patent/EP3652349A1/en active Pending
- 2018-07-10 CA CA3069515A patent/CA3069515A1/en active Pending
- 2018-07-10 WO PCT/US2018/041480 patent/WO2019014246A1/en not_active Ceased
- 2018-07-10 AU AU2018300007A patent/AU2018300007A1/en not_active Abandoned
- 2018-07-10 CN CN201880058523.8A patent/CN111295454A/zh active Pending
- 2018-07-10 US US16/629,512 patent/US11821042B2/en active Active
- 2018-07-10 SG SG11202000132WA patent/SG11202000132WA/en unknown
- 2018-07-10 JP JP2020500887A patent/JP7197556B2/ja active Active
-
2020
- 2020-01-06 IL IL271849A patent/IL271849A/en unknown
-
2023
- 2023-04-12 US US18/299,558 patent/US20240110246A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Park et al. | Yes‐associated protein 1 and transcriptional coactivator with PDZ‐binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma | |
| Gutierrez et al. | Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia | |
| JP6750069B2 (ja) | 癌の分類および使用法 | |
| US11058903B2 (en) | Methods for identifying and treating cachexia or pre-cachexia using an inhibitor of rage | |
| US11447831B2 (en) | Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists | |
| US20190192517A1 (en) | Treatment of squamous cell carcinomas with inhibitors of erk | |
| CN103382503B (zh) | Egfr基因19号外显子19种缺失突变检测试剂盒及检测方法 | |
| EP2407783A1 (en) | A method for pharmacologically profiling compounds | |
| US20210130903A1 (en) | Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment | |
| CN107663533A (zh) | 一种肺癌EGFR L858R和19Del的ddPCR检测方法及应用 | |
| WO2020046966A1 (en) | Treatment of adenocarcinomas with mapk pathway inhibitors | |
| KR20220123064A (ko) | Cdk12/13 억제제에 의한 암 치료 | |
| KR20180042819A (ko) | Hsp90 억제제 내성 세포주 및 이를 이용한 항암제 스크리닝 방법 | |
| WO2012112245A1 (en) | Modulation of phosphatidylinositol-5-phosphate-4-kinase activity | |
| JP6323979B2 (ja) | うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット | |
| Zhao et al. | BZW1 as an oncogene is associated with patient prognosis and the immune microenvironment in glioma | |
| US20130004424A1 (en) | Methods for determining agents targeting mena isoforms and uses thereof for diagnosis and treatment of metastatic tumors | |
| CN109554469A (zh) | T细胞急性淋巴性白血病的肿瘤细胞及其分子标志 | |
| KR102132222B1 (ko) | 항암제 내성 진단 마커로서의 miR-143-3p 및 miR-373-5p, 및 이의 이용 | |
| Du et al. | A novel break site of EML4‐ALK report and a rare PRKAR1A‐ALK report analyzed by different ALK detection platforms in non‐small cell lung cancer patients | |
| JPWO2012002274A1 (ja) | 培養細胞を用いたｓ１ｐリアーゼ阻害剤のスクリーニング方法 | |
| WO2012130720A2 (en) | PREDICTION OF RESPONSIVENESS TO PIK3/mTOR INHIBITORS | |
| CN105838781A (zh) | ddPCR技术监测伊马替尼(格列卫)/尼罗替尼继发耐药的方法 | |
| Hao et al. | Discovery of anti-tumor small molecule lead compounds targeting the SH3 domain of c-Src protein through virtual screening and biological evaluation | |
| CN115887657A (zh) | Jak2/stat3抑制剂单独或联合卡铂在制备乳腺癌治疗药物中的应用 |